Cardiovascular outcomes of intravenous iron in perspective of clinical trials and the use of different iron preparations by Toblli, Jorge Eduardo et al.
International Journal of Cardiology 187 (2015) 196–197
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdLetter to the EditorCardiovascular outcomes of intravenous iron in perspective of clinical
trials and the use of different iron preparationsJorge E. Toblli ⁎, Gabriel Cao, Margarita Angerosa
Hospital Alemán, School of Medicine, University of Buenos Aires, Argentina⁎ Corresponding author at: Hospital Alemán, School of
Aires, Av. Pueyrredon 1640, 1118 Buenos Aires, Argentina
E-mail address: jorgetoblli@ﬁbertel.com.ar (J.E. Toblli)
http://dx.doi.org/10.1016/j.ijcard.2015.03.327
0167-5273/© 2015 The Authors. Published by Elsevier Irea r t i c l e i n f oArticle history:
Received 5 March 2015
Accepted 20 March 2015
Available online 21 March 2015
Keywords:
Oxidative stress
Intravenous iron
Iron sucrose similar
Generics
Anemia
Iron deﬁciency
in patients with CHF and iron deﬁciency (FAIR-HF, CONFIRM-HF), i.v.
iron (ferric carboxymaltose)-treated patients showed fewer hospitali-
zations for cardiovascular reasons in addition to signiﬁcant functional
improvements [5,6]. Based on the FAIR-HF results, the European Society
for Cardiology considered i.v. iron for the treatment of iron deﬁciency in
heart failure patients in its 2012 guideline and recommended an iron
deﬁciency screening in all patients suspected of having heart failure [7].
Effects of different i.v. iron complexes (iron sucrose, ferric gluconate,
iron dextran and ferric carboxymaltose) on oxidative stress and inﬂam-
mation (i.e. established risk factors of cardiovascular outcomes in CKD
patients) have been investigated in a head-to-head comparison in a
non-anemic rat model [8]. Analysis of cardiac, renal and hepatic tissueTo the Editor:
In November 2014, an article by Kuo et al. [1] suggested a role of an
intravenous (i.v.) iron sucrose preparation in leukocyte–endothelium
interactions and atherogenesis based on results in cell culture assays, a
mouse model and patients with chronic kidney disease (CKD). The au-
thors reported that circulating mononuclear cells (MNCs) isolated
from CKD patients who have received the iron sucrose preparation pro-
duced higher levels of intracellular superoxide than those fromuntreat-
ed CKD patients or healthy subjects. Also serum levels of soluble cell
adhesion molecules were higher than in the control subjects. These re-
sultswere corroborated by results inmicewith uninephrectomy and by
in vitro assays using cultured human aortic endothelial cells. Overall, the
authors concluded that therapeutic iron may have a causative role in
cardiovascular complications in patients with CKD.
This conclusion should be considered only with caution and in the
context of the used iron preparation. Actually, a double-blind, placebo-
controlled clinical study that investigated i.v. iron sucrose in anemic pa-
tients with CKD and chronic heart failure (CHF) did not report cardio-
vascular complications after 6 months follow-up but showed
improvements in myocardial functional parameters (New York Heart
Association [NYHA] score, 6-minute walk test) and cardiac dimensions
in the i.v. iron group [2,3]. Recently presented 5-year follow-up data
showed signiﬁcantly lower hospitalization and mortality rates in theMedicine, University of Buenos
.
.
land Ltd. This is an open access articli.v. iron group [4]. In two other double-blind, placebo-controlled studies
samples in this study showed signiﬁcant signs of oxidative stress and in-
ﬂammation in response to ferric gluconate, a compound known to re-
lease high amounts of labile iron [9], whereas iron sucrose and ferric
carboxymaltose showed no signiﬁcant changes compared with saline
control. Similarly, a study in CHF patients randomized to 16 weeks of
iron sucrose or no treatment showed no difference in malondialdehyde
levels (a marker of lipid peroxidation) between the two groups [10].
Notably, also a comparison of the iron sucrose originator product
(Venofer®, Vifor Pharma, Switzerland) and six different follow-on prep-
arations (better called iron sucrose similars) showed signiﬁcant differ-
ences in oxidative stress and inﬂammatory response markers [11].
Based on information that is only available from the supplementary
material of the Kuo article (Nang-Kuang Pharmaceutical mentioned as
manufacturer of the used iron sucrose), we assume that an iron sucrose
similar, namely Fe-Back, has been used in their studies [1]. In the head-
to-head comparison of iron sucrose originator and iron sucrose similars
[11], Fe-Back was associated with signiﬁcantly greater increases in oxi-
dative stress, markers of inﬂammation (tumor necrosis factor-α,
interleukin-6), off-target iron deposition, elevation of liver enzymes
and proteinuria than the iron sucrose originator. Physico-chemical anal-
yses further revealed a three-fold higher molecular weight of Fe-Back
compared with the iron sucrose originator (162 kDa vs. 45.7 kDa; re-
quirement according to US Pharmacopeia is 34–60 kDa). This suggests
that Fe-Back is either a very different molecule or forms substantial
aggregates. Moreover, Fe-Back had a completely differently shaped
polarogram compared with the originator product, indicating a very dif-
ferent redox behavior of the similar product, and also exhibited high lot-
to-lot variability in physico-chemical parameters, whichmay result from
variations in themanufacturing processes. Overall, Fe-back can hardly be
considered pharmaceutically equivalent to the iron sucrose originator.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Markers of oxidative stress, nitrosative stress and inﬂammatory response in the aorta (Ao)
andmesenteric arteries (MA) of non-anemic rats treatedwith iron sucrose originator, the
iron sucrose similar Fe-Back or saline control (Day 28).
Mean SD Iron sucrose(Venofer®)
(n = 8)
Iron sucrose(Fe-Back)
(n = 8)
Control(Saline)
(n = 8)
MDA (μM/mg protein)
A) Ao 3.3 ± 0.4 13.7 ± 0.9⁎ 2.9 ± 0.5
B) MA 3.4 ± 0.5 14.1 ± 1.1⁎ 3.0 ± 0.3
GSH/GSSG ratio
A) Ao 6.1. ± 0.6 3.8 ± 0.3⁎ 6.8 ± 0.5
B) MA 5.9 ± 0.5 3.5 ± 0.2⁎ 6.6 ± 0.4
GPx (U/mg protein)
A) Ao 296.3 ± 25.8 386.4 ± 21.1⁎ 275.8 ± 20.2
B) MA 311.9 ± 17.9 394.0 ± 24.0⁎ 300.6 ± 11.7
NT (% positive staining)
A) Ao 1.1 ± 0.4 9.0 ± 1.3⁎ 0.9 ± 0.3
B) MA 1.3 ± 0.5 9.3 ± 2.0⁎ 1.1 ± 0.4
eNOS (% positive staining)
A) Ao 2.3 ± 0.6 0.8 ± 0.4⁎ 2.7 ± 0.7
B) MA 2.9 ± 0.3 0.6 ± 0.2⁎ 3.0 ± 0.4
VCAM-1 (% positive staining)
A) Ao 1.4 ± 0.5 6.9 ± 1.2⁎ 1.1 ± 0.4
B) MA 1.5 ± 0.6 7.3 ± 1.1⁎ 1.2 ± 0.3
IL-6 (% positive staining)
A) Ao 1.8 ± 0.4 8.6 ± 2.3⁎ 1.4 ± 0.3
B) MA 2.0 ± 0.3 10.5 ± 2.5⁎ 1.8 ± 0.3
Ao aorta; eNOS endothelial nitric oxide synthase; GPx glutathioneperoxidase; GSSG oxi-
dized glutathione; GSH reduced glutathione; IL interleukine; MA mesenteric arteries;
MDA malondialdehyde; NT nitrotyrosine; VCAM vascular cell adhesion molecule.
⁎ p b 0.01 versus iron sucrose originator and saline control.
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effects of Fe-Back and the iron sucrose originator on the aorta andmes-
enteric arteries in our established non-anemic rat model (i.v. adminis-
tration of 40 mg iron/kg body weight on Days 0, 7, 14, 21 and 28;
control group treatedwith saline) [11]. All animals used in the study re-
ceived humane care and the study protocol complied with the guide-
lines of Hospital Alemán, University of Buenos Aires, Argentina.
Analysis of tissue homogenates revealed signiﬁcant distortion of
markers of oxidative stress, nitrosative stress and inﬂammatory re-
sponse in the aorta and mesenteric arteries in the Fe-Back group com-
pared with the iron sucrose and the saline control group (Table 1).
Conversely, no statistically signiﬁcant differences were observed be-
tween the iron sucrose originator and the control group.
While Kuo et al. correctly imply that excessive i.v. iron administra-
tionmay be associatedwith potential adverse cardiovascular outcomes,
our results, although obtained in a differentmodel, suggest that vascular
wall damage as reported by Kuo et al. could be more likely linked to a
particular iron sucrose preparation, in that case Fe-Back, rather than
i.v. iron in general.
Notably, the European Medicines Agency (EMA) has published a
draft reﬂection paper highlighting EMA's concerns regarding the cur-
rent experimental and regulatory assessment of iron-based nanoparti-
cles and suggesting non-clinical and clinical data requirements for
evaluation [12]. Similar discussions are also ongoing in the US Food
and Drug Administration [13].
In fact, i.v. iron complexes are so-called non-biological complex
drugs that are not composed of a single and fully characterizable sub-
stance such as common small molecule therapeutic substances. This
complexity makes them prone to changes in their structure and biolog-
ical properties even by minute variations in the manufacturing process
[14,15]. Therefore, evaluation of products developedwith reference to a
complex originator drug should include appropriate comparative
clinical and/or nonclinical studies that evaluate pharmacokinetics,
pharmacodynamics and safety as well as efﬁcacy in relevant patientpopulations. Unless therapeutic equivalence and similar safety proﬁles
are shown in comparative studies, experts discourage interchange and
automatic substitution between non-biological complex drugs and
their follow-on (similar) products [16]. Publications should clarify
from the outset whether an originator or a similar productwas used, es-
pecially if the study results may impact clinical decision making and
treatment choice.Conﬂict of interest
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